Marcin Kowanetz

30.8k total citations · 4 hit papers
109 papers, 12.3k citations indexed

About

Marcin Kowanetz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Marcin Kowanetz has authored 109 papers receiving a total of 12.3k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 26 papers in Immunology. Recurrent topics in Marcin Kowanetz's work include Cancer Immunotherapy and Biomarkers (73 papers), Lung Cancer Treatments and Mutations (25 papers) and Cancer Genomics and Diagnostics (19 papers). Marcin Kowanetz is often cited by papers focused on Cancer Immunotherapy and Biomarkers (73 papers), Lung Cancer Treatments and Mutations (25 papers) and Cancer Genomics and Diagnostics (19 papers). Marcin Kowanetz collaborates with scholars based in United States, France and Spain. Marcin Kowanetz's co-authors include Alan Sandler, Napoleone Ferrara, Federico Cappuzzo, Aristidis Moustakas, Achim Rittmeyer, Carl‐Henrik Heldin, Robert M. Jotte, Delvys Rodríguez‐Abreu, Fabrice Barlési and Daniil Stroyakovskiy and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Marcin Kowanetz

105 papers receiving 12.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

2018 2.6k citations Mark A. Socinski, Robert M. Jotte et al. profile →
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

2016 2.1k citations Alexander I. Spira, Marcus Ballinger et al. profile →
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

2019 1.1k citations Howard West, Michael McCleod et al. The Lancet Oncology profile →
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

2019 688 citations Tony Mok, Robert M. Jotte et al. profile →

Peers

Countries citing papers authored by Marcin Kowanetz

Since Specialization

Citations

This map shows the geographic impact of Marcin Kowanetz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcin Kowanetz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcin Kowanetz more than expected).

Fields of papers citing papers by Marcin Kowanetz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcin Kowanetz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcin Kowanetz. The network helps show where Marcin Kowanetz may publish in the future.

Co-authorship network of co-authors of Marcin Kowanetz

This figure shows the co-authorship network connecting the top 25 collaborators of Marcin Kowanetz. A scholar is included among the top collaborators of Marcin Kowanetz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcin Kowanetz. Marcin Kowanetz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004) 2024 ·Journal of Thoracic Oncology ·Alexander I. Spira, Byoung Chul Cho, Enriqueta Felip, Edward B. Garon, Kōichi Goto, Melissa Johnson, Natasha B. Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Chih‐Hsin Yang, Xiaoqian Lu, Yong Jiang, (unknown), (unknown), Marcin Kowanetz, Shirley Wang, John T. Le, Jerry Y. Hsu, Caicun Zhou	0
2	FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004) 2024 ·Lung Cancer ·Alexander I. Spira, Byoung Chul Cho, Enriqueta Felip, Edward B. Garon, Kōichi Goto, Melissa Johnson, Natasha B. Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Chih‐Hsin Yang, Xiaoqian Lu, Yong Jiang, (unknown), (unknown), Marcin Kowanetz, Shirley Wang, John T. Le, Jerry Y. Hsu, Caicun Zhou	2
3	Abstract 1964: Furmonertinib is a brain-penetrant EGFR TKI highly active in uncommon EGFR mutations, including PACC and exon 20 insertions 2024 ·Cancer Research ·Monique B. Nilsson, Zineb Mounir, Luna Musib, Junqin He, Xiaoxing Yu, Qing Li, (unknown), John V. Heymach, Jerry Y. Hsu, Stuart Lutzker, Xiuning Le, Marcin Kowanetz	0
4	C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients 2021 ·PLoS ONE ·Namrata S. Patil, Wei Zou, Simonetta Mocci, Alan Sandler, Marcus Ballinger, Susan Flynn, Marcin Kowanetz, Priti S. Hegde	7
5	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial breakdown → 2019 ·The Lancet Oncology ·Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter, Hans‐Georg Kopp, Davey B. Daniel, Steven McCune, Tarek Mekhail, Alona Zer, Niels Reinmuth, Ahad A. Sadiq, Alan Sandler, Wei Lin, Tania Ochi Lohmann, Venice Archer, Lijia Wang, Marcin Kowanetz, Federico Cappuzzo	1137
6	Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma 2018 ·Cancer Immunology Research ·Benjamin Solomon, Richard J. Young, Mathias Bressel, Damien Urban, Shona Hendry, Alesha A. Thai, Christopher Angel, (unknown), Marcin Kowanetz, Tsien Fua, June Corry, Stephen B. Fox, Danny Rischin	100
7	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC 2018 ·Journal of Thoracic Oncology ·David R. Spigel, Jamie E. Chaft, Scott Gettinger, Bo H. Chao, Luc Dirix, Peter Schmid, Laura Q.M. Chow, Rodney J. Hicks, Larry Leon, Jill Fredrickson, Marcin Kowanetz, Alan Sandler, Roel Funke, Naiyer A. Rizvi	114
8	Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST) 2017 ·Annals of Oncology ·David Fabrizio, Christine M. Malboeuf, Daniel S. Lieber, Shan Zhong, Jianzhong He, Elizabeth C. White, Michael J. Coyne, Jacob Silterra, Tina Brennan, Jun Ma, Mark Kennedy, Erica Schleifman, Sarah Paul, (unknown), David S. Shames, Craig Cummings, Eric Peters, Marcin Kowanetz, Doron Lipson, Geoff Otto	14
9	Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150) 2017 ·Annals of Oncology ·Martin Reck, Mark A. Socinski, Federico Cappuzzo, Francesco Orlandi, (unknown), Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, (unknown), Fabrice Barlési, Gene Grant Finley, (unknown), (unknown), (unknown), (unknown), Marcin Kowanetz, Ariel López-Chávez, (unknown), Robert M. Jotte	32
10	Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study 2017 ·Annals of Oncology ·S. Gadgeel, Marcin Kowanetz, Wenbo Zou, Fred R. Hirsch, Keith M. Kerr, David R. Gandara, Fabrice Barlési, (unknown), Mark L. McCleland, Hartmut Koeppen, M. Ballinger, A. Sandler, Priti S. Hegde, Achim Rittmeyer	13
11	Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer 2017 ·Annals of Oncology ·Marius Ilié, Edith Szafer‐Glusman, Véronique Hofman, Emmanuel Chamorey, Salomé Lalvée, Éric Selva, Sylvie Leroy, Charles‐Hugo Marquette, Marcin Kowanetz, (unknown), Elizabeth A. Punnoose, Paul Hofman	153
12	Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC 2017 ·Annals of Oncology ·Tony Mok, Shirish M. Gadgeel, (unknown), Vamsidhar Velcheti, Sylvia Hu, Todd Riehl, Erica Schleifman, (unknown), Simonetta Mocci, David S. Shames, S. Phan, (unknown), (unknown), Marcin Kowanetz, (unknown), Mark A. Socinski	12
13	OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study 2017 ·Journal of Thoracic Oncology ·Marina Chiara Garassino, Naiyer A. Rizvi, Benjamin Besse, Pasi A. Jänne, Daniel C. Christoph, Solange Peters, Chee‐Keong Toh, Takayasu Kurata, Enric Carcereny, Marianna Koczywas, Enriqueta Felip, Jamie E. Chaft, Jiaheng Qiu, Marcin Kowanetz, Shelley Coleman, Simonetta Mocci, Alan N. Sandler, Scott Gettinger, Melissa L. Johnson	13
14	Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC 2016 ·Annals of Oncology ·Fabrice Barlési, K. Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, (unknown), Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, David R. Gandara, C.H. Barrios, (unknown), (unknown), Marcin Kowanetz, M. Ballinger, Daniel Waterkamp, A. Sandler, Achim Rittmeyer	56
15	PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study 2016 ·Journal of Thoracic Oncology ·Michael S. Gordon, Roy S. Herbst, Leora Horn, Jean‐Charles Soria, Leena Gandhi, Enriqueta Felip, Lecia V. Sequist, David R. Spigel, Scott Antonia, Ani Sarkis Balmanoukian, Philippe A. Cassier, Bo Liu, Marcin Kowanetz, Carol O’Hear, Marcella Fassò, Alan Sandler, Scott Gettinger	2
16	Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC 2016 ·Annals of Oncology ·Marcin Kowanetz, Wei Zou, David S. Shames, (unknown), Naiyer A. Rizvi, Alexander I. Spira, Garrett M. Frampton, Vincent Lévêque, Shannon L. Flynn, Simonetta Mocci, G. Shankar, Roel Funke, M. Ballinger, Daniel Waterkamp, A. Sandler, Garret M. Hampton, Lukas C. Amler, Priti S. Hegde, Matthew D. Hellmann	34
17	Differential drug class‐specific metastatic effects following treatment with a panel of angiogenesis inhibitors 2012 ·The Journal of Pathology ·Alicia S. Chung, Marcin Kowanetz, Xiumin Wu, Guanglei Zhuang, Hai Ngu, David Finkle, László G. Kömüves, Franklin Peale, Napoleone Ferrara	71
18	Transcriptional Induction of Salt-inducible Kinase 1 by Transforming Growth Factor β Leads to Negative Regulation of Type I Receptor Signaling in Cooperation with the Smurf2 Ubiquitin Ligase 2012 ·Journal of Biological Chemistry ·Peter Lönn, Michael Vanlandewijck, Erna Raja, Marcin Kowanetz, Yukihide Watanabe, Katarzyna Kowanetz, Eleftheria Vasilaki, Carl‐Henrik Heldin, Aristidis Moustakas	29
19	Blocking Vascular Endothelial Growth Factor-A Inhibits the Growth of Pituitary Adenomas and Lowers Serum Prolactin Level in a Mouse Model of Multiple Endocrine Neoplasia Type 1 2008 ·Clinical Cancer Research ·Nina Korsisaari, Jed Ross, Xiumin Wu, Marcin Kowanetz, (unknown), (unknown), Jeffrey Eastham‐Anderson, William F. Forrest, Nicholas van Bruggen, Franklin Peale, Napoleone Ferrara	49
20	EPIDERMAL GROWTH FACTOR AND PRO-INFLAMMATORY CYTOKINES REGULATE THE EXPRESSION OF COMPONENTS OF PLASMINOGEN ACTIVATION SYSTEM IN U373-MG ASTROCYTOMA CELLS 2001 ·Cytokine ·Aneta Kasza, Marcin Kowanetz, (unknown), Barbara Witek, Tomasz Kordula, Aleksander Koj	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact